Search our Database of Scientific Publications and Authors

I’m looking for a

    3998 results match your criteria Biology of Blood and Marrow Transplantation[Journal]

    1 OF 80

    Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.
    Biol Blood Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany. Electronic address:
    Successful collection of peripheral blood stem cells (PBSCs) depends on the optimal orchestration of mobilization chemotherapy, granulocyte-colony-stimulating factor (G-CSF) application, and CD34+ cell number assessment in the peripheral blood (PB). However, determining the optimal timing in accordance to the applied chemomobilization regimen can be challenging. While most centers apply their own local timing schedules, a reliable timetable including the currently most often used mobilization regimens is lacking. Read More

    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical BMT.
    Biol Blood Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address:
    With posttransplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, nonmyeloablative HLA-haploidentical (NMA haplo) and HLA-matched blood or marrow transplantation (BMT) have comparable outcomes. Early discontinuation of immunosuppression may reduce relapse, as well as improve immune reconstitution, but may increase GVHD. We conducted a prospective trial of NMA haplo BMT for patients with hematologic malignancies (median age, 61), evaluating the safety of early discontinuation of tacrolimus. Read More

    Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Department of Pediatric Hematology and Stem Cell Transplantation, United St.István and St. László Hospital, Budapest, Hungary.
    Hematopoietic stem cell transplantation- (HSCT-) associated thrombotic microangiopathy (TA-TMA) is a multifactorial complication, and its prediction is largely unresolved.Our aim was to analyze changes of complement profile after HSCT in order to identify potential markers of TA-TMA development. Thirty- three consecutive pediatric patients (9. Read More

    Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium - HAPLO2016, San Diego, California, December 1, 2016.
    Biol Blood Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
    The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ selection, 'mega-dose' of purified CD34+ cells, or selective depletion of T-cells) or newer platforms of in vivo depletion of T cells, with either post-transplant high-dose cyclophosphamide (PTCy) or intensified immune suppression, have contributed to better outcomes, with survival that is similar to HLA-match donor transplantation. Further efforts are on the way to control viral reactivation using modified T cells, improve immunologic reconstitution and decreased relapse rate post-transplant using donor-derived cellular therapy products like genetically modified donor lymphocytes or NK cells. Read More

    Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150).
    Biol Blood Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Seoul National University Hospital, Seoul, Republic of Korea.
    This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2) prior to ASCT. Read More

    Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents.
    Biol Blood Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    University Hospital Eppendorf, Hamburg, Germany.
    The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM). We examined the SPM rate in MM patients who were enrolled in the prospective observational Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma (CALM) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation (auto-HSCT). Read More

    Sequential Conditioning with Thiotepa in T-Cell Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematological Malignancies: Comparison with Matched Related, Haplo-Mismatched and Unrelated Donors.
    Biol Blood Marrow Transplant 2018 Jan 11. Epub 2018 Jan 11.
    Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France; INSERM, UMRs 938, Paris, France; Sorbonne Universités, UPMC Paris 6, Paris, France. Electronic address:
    The results of conventional allogeneic stem cell transplantation (SCT) in refractory hematological malignancies are poor. Sequential strategies have shown promising results in refractory acute myeloid leukemia (AML), but have not been validated in a haploidentical (Haplo) setting. We developed a new sequential approach combining chemotherapy with broad anti-tumor activity (thiotepa 10 mg/kg, etoposide 400 mg/m2, cyclophosphamide 1600 mg/m2 from Day-15 to -10), followed after 3 days of rest by reduced-intensity conditioning regimen (fludarabine 150 mg/m2, intravenous busulfan 6. Read More

    Blood and Marrow Transplant Clinical Trials Network Report on Development of Novel Endpoints and Selection of Promising Approaches for Graft-Versus-Host Disease Prevention Trials.
    Biol Blood Marrow Transplant 2018 Jan 8. Epub 2018 Jan 8.
    Dana Farber Cancer Institute, Boston, MA.
    Graft versus host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here, we report a benchmark analysis to evaluate the performance of six GVHD prevention strategies tested at single institutions compared to a large multicenter outcomes database as a control. Read More

    Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected or Unmodified Hematopoietic Stem Cells Transplants.
    Biol Blood Marrow Transplant 2018 Jan 8. Epub 2018 Jan 8.
    Adult Bone Marrow Transplantation Service, Department of Medicine; Memorial Sloan Kettering Cancer Center, New York, N.Y, U.S.A; Weill Cornell Medical College, New York, N.Y, U.S.A.
    Purpose: To compare transplant outcomes in patients with advanced myelodysplastic syndrome (MDS) after CD34+ selected or unmodified allografts.

    Patients And Methods: This analysis included initially 181 patients; 60 underwent CD34+ selected transplant and 121 had an unmodified transplant. Due to significant differences in disease characteristics, the analysis was limited to patients who had <10% blasts prior to transplant (N=145). Read More

    Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
    Biol Blood Marrow Transplant 2018 Jan 4. Epub 2018 Jan 4.
    Children's University Hospital, University of Tuebingen, Tuebingen, Germany. Electronic address:
    Background: Pediatric patients with refractory or relapsed metastatic neuroblastoma (NBL) have a poor prognosis despite autologous stem cell transplantation (SCT). Allogeneic SCT from haploidentical donors had remarkable alloreactive effects in leukemia patients; hence, we evaluated this approach in children with very high-risk NBL.

    Methods: We analyzed data from two prospective phase I/II trials. Read More

    Peri-Transplant RBC Transfusion is Associated with Increased Risk of GvHD after Allogeneic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 Jan 4. Epub 2018 Jan 4.
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. Electronic address:
    More than 90% of allogeneic hematopoietic stem cell transplant (allo-HSCT) patients receive red blood cell (RBC) or platelet transfusions in the peritransplant period. We tested the hypothesis that transfusions are associated with development of severe acute graft-versus-host disease (grade III/IV aGvHD) or mortality in allo-HSCT in a retrospective study of 322 consecutive patients receiving allogeneic bone marrow or G-CSF-mobilized blood stem cell grafts for hematological malignancies. Counting RBC and platelet units between day -7 pre-transplant and +27 post-transplant, but excluding transfusions administered after a diagnosis of aGvHD, yielded medians of 5 RBC and 2 platelet units transfused. Read More

    CD34+ Selection Vs. Reduced-Intensity Conditioning and Unmodified Graft for Allogeneic Hematopoietic Cell Transplantation in Patients with AML and MDS > 50 Years.
    Biol Blood Marrow Transplant 2018 Jan 2. Epub 2018 Jan 2.
    Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College; New York, NY. Electronic address:
    Reduced-intensity conditioning (RIC) and t-cell depletion (TCD) through CD34+ selection without the use of post-transplant immunosuppression are 2 strategies used to reduce non-relapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of both approaches (RIC and TCD), we evaluated the outcomes of AML and MDS patients > 50 years who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable between patients receiving TCD (n=204) and RIC (n=151) except for more unrelated donors (68% vs. Read More

    Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies.
    Biol Blood Marrow Transplant 2018 Jan 2. Epub 2018 Jan 2.
    Westmead Institute of Medical Research, University of Sydney, Westmead, Australia; Blood and Marrow Transplant Unit, Westmead Hospital, Australia; Sydney Cellular Therapies Laboratory, Westmead, Australia; Sydney Medical School, University of Sydney, Camperdown, Australia. Electronic address:
    Current techniques to assess chimerism after hematopoietic stem cell transplantation (HSCT) are limited in both sensitivity and precision. These drawbacks are problematic in the context of cellular therapies which frequently result in microchimerism (donor chimerism <1%). We have developed a highly sensitive droplet digital PCR (ddPCR) assay using commercially available regents with good performance throughout the range of clinically relevant chimerism measurements, including microchimerism. Read More

    Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Non-Malignant Diseases.
    Biol Blood Marrow Transplant 2017 Dec 29. Epub 2017 Dec 29.
    Hematopoetic Stem Cell Transplant Unit, Hematology-Oncology, G Gaslini Institute, Genoa.
    Background: It is recognized that chimerism following hematopoietic stem cell transplantation (HSCT) is a dynamic process. The aims of this study were to describe the evolution of chimerism in children with non-malignant diseases who underwent allogeneic HSCT, and to analyze the risk factors influencing chimerism status.

    Procedure: 101 HSCTs were performed in 85 patients with non-malignant diseases. Read More

    Community Risk Score for Evaluating Healthcare Disparities in Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 29. Epub 2017 Dec 29.
    Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

    The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations From the ASBMT Pharmacy Sig.
    Biol Blood Marrow Transplant 2017 Dec 29. Epub 2017 Dec 29.
    Wake Forest Baptist Health, Medical Center Blvd. Winston Salem, NC, 27157.
    Pharmacists are increasingly recognized as an essential member of the multi-disciplinary team for hematopoietic cell transplant (HCT) patients. However, until recently, their educational background, required training, and potential roles have not been well described. Therefore, the purpose of this manuscript is to provide supporting evidence for the HCT Clinical Pharmacist Role Description, which has been endorsed by several organizations including ASBMT. Read More

    Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime.
    Biol Blood Marrow Transplant 2017 Dec 29. Epub 2017 Dec 29.
    Department of Medicine, Augusta University Medical Center, Augusta, GA; Georgia Cancer Center, Augusta, GA.
    Empiric antimicrobials are frequently utilized in the pre-engraftment phase after hematopoietic cell transplantation (HCT). Recent evidence suggests an increased risk of acute kidney injury (AKI) from combination of vancomycin with piperacillin/tazobactam; however, this has not specifically been evaluated in the HCT population. A single-center, retrospective review was conducted from 2011-2017 on 110 autologous and 60 allogeneic HCT patients with the primary objective of comparing incidence of AKI for those who received vancomycin with piperacillin/tazobactam versus vancomycin with cefepime in the pre-engraftment phase. Read More

    Comparison of Autologous Stem Cell Transplantation Versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Biol Blood Marrow Transplant 2017 Dec 28. Epub 2017 Dec 28.
    Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Address: 188, Shizi Street, Suzhou, Jiangsu Province, 215006, China; Institute of Blood and Marrow transplantation, Soochow University, Address: 199, Renai Road, Suzhou, Jiangsu Province, 215006, China; Collaborative Innovation Center of Hematology, Soochow University, Address: 199, Renai Road, Suzhou, Jiangsu Province, 215006, China. Electronic address:
    Stem cell transplantation (SCT) is an attractive post-remission treatment option for patients with intermediate-risk acute myeloid leukemia (AML) and for some favorable-risk AML patients with additional non-genetic risk factors. Autologous SCT (auto-SCT) and haplo-identical donor SCT (haplo-SCT) are the widely used alternatives in case of a lack of a human leukocyte antigen (HLA)-matched donor. However, limited data have been published on the direct comparison between these two transplant types. Read More

    Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
    Biol Blood Marrow Transplant 2017 Dec 28. Epub 2017 Dec 28.
    Loyola University Medical Center, Maywood, IL.
    Based on promising pilot data, a Phase II tandem autologous hematopoietic stem cell transplant (AHSCT) trial for relapsed/refractory Hodgkin Lymphoma (HL) was performed in the US intergroup setting to determine if long-term progression-free survival (PFS) could be improved. Patients were enrolled after salvage therapy and stem cell collection. Sensitivity to salvage was defined by 1999 Standardized Response Criteria and did not include FDG-PET. Read More

    The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
    Biol Blood Marrow Transplant 2017 Dec 28. Epub 2017 Dec 28.
    Washington University School of Medicine, St Louis, MO.
    For patients with hematologic malignancies, allogeneic hematopoietic cell transplantation (alloHCT) offers a potential curative treatment option, primarily due to an allogeneic immune response against recipient tumor cells (ie, graft-versus-leukemia [GVL] activity). However, many recipients of alloHCT develop graft-versus-host disease (GVHD), in which allogeneic immune responses lead to the damage of healthy tissue. GVHD is a leading cause of nonrelapse mortality and a key contributor to morbidity among patients undergoing alloHCT. Read More

    Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared to Matched Unrelated Donor Stem Cells in Older Adults.
    Biol Blood Marrow Transplant 2017 Dec 27. Epub 2017 Dec 27.
    Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address:
    Haplo/cord transplantation combines an umbilical cord blood (UCB) graft with CD34-selected haploidentical cells and results in rapid hematopoietic recovery followed by durable UCB engraftment. We compared outcomes of transplants in older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) who received either HLA-matched unrelated donor cells (MUD) or haplo/cord grafts. Between 2007 and 2013, 109 adults ages 50 and older underwent similar reduced intensity conditioning (RIC) with fludarabine and melphalan and antibody-mediated T-cell depletion for AML (n=83) or high risk MDS (n=26) followed by either a MUD (n=68) or haplo/cord (n=41) graft. Read More

    Stem Cell Transplantation and Informatics - Current Considerations.
    Biol Blood Marrow Transplant 2017 Dec 27. Epub 2017 Dec 27.
    Informatics strategies and applications available to stem cell transplant (SCT) programs are diverse and changing rapidly. While most hospitals have electronic medical records (EMR), few are equipped with specialized SCT applications. Most EMR do not contain critical elements to support SCT practice and research. Read More

    Re-Vaccination Following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
    Biol Blood Marrow Transplant 2017 Dec 27. Epub 2017 Dec 27.
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA.
    Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Due to decreased vaccine rates among the general population causing loss of herd immunity, we aimed to establish the safety and efficacy of revaccinating multiple myeloma patients on lenalidomide maintenance (LM). Of the 122 patients who were vaccinated after aHCT between 2010-2014 at MSKCC, 91 (75%) were on LM. Read More

    Low Body Mass Index is Associated with Increased Risk of Acute GvHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: a Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party.
    Biol Blood Marrow Transplant 2017 Dec 27. Epub 2017 Dec 27.
    Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco; Hopital Saint Antoine, Service d'Hématologie et thérapie cellulaire, Paris, France.
    Body mass index (BMI) might influence outcomes after allogeneic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients aged 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Read More

    Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation.
    Biol Blood Marrow Transplant 2017 Dec 26. Epub 2017 Dec 26.
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, New York. Electronic address:
    A strategy to rapidly determine if a matched unrelated donor (URD) can be secured for allograft recipients is needed. We sought to validate the accuracy of 1) HapLogic™ match predictions, and, 2) a resultant novel Search Prognosis (SP) patient categorization that could predict 8/8 HLA-matched URD(s) likelihood at search initiation. Patient prognosis categories at search initiation were correlated with URD confirmatory typing results. Read More

    Long-Term Safety of Short-Term Administration of Filgrastim (rhG-CSF) and Leukophresis Procedure in Healthy Children: Application of Peripheral Blood Stem Cell Collection in Pediatric Donors.
    Biol Blood Marrow Transplant 2017 Dec 25. Epub 2017 Dec 25.
    Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
    Administration of filgrastim (recombinant human granulocyte colony-stimulating factor [rhG-CSF]) (Neupogen) in healthy donors to mobilize hematopoietic stem cells (HSCs) is a widespread practice in adults. Application of peripheral blood stem cell (PBSC) collection in normal pediatric donors is scarce due to ethical issues. Hence, there are insufficient data on the long-term impact of PBSC procedure in healthy children. Read More

    Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
    Biol Blood Marrow Transplant 2017 Dec 19. Epub 2017 Dec 19.
    Department of Pediatrics, Section Immunology, Hematology and Stem Cell Transplantation, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:
    Autoimmune or alloimmune cytopenia (AIC) is a known rare complication of hematopoietic stem cell transplantation (SCT). AIC after SCT is considered difficult to treat and is associated with high morbidity and mortality. In this retrospective study in pediatric patients we evaluated incidence, outcome, potential risk factors, and current treatment strategies. Read More

    Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN.
    Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n=109), 1 (n=93), or 0 cycles (n=322) of consolidation prior to myeloablative alloHCT from 2008-2012. Read More

    Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Biol Blood Marrow Transplant 2017 Dec 20. Epub 2017 Dec 20.
    Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.
    In this prospective, randomized, phase II "pick the winner" trial we assessed the efficacy of transplant conditioning with treosulfan/fludarabine ± 2 Gy total body irradiation (TBI) in reducing post-transplant relapse in 100 patients, aged 2 to 70 years (median, 57), with myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (n = 51) or acute myeloid leukemia (AML; n = 49). Patients received i.v. Read More

    Risk of Exposure to Zika Virus and Impact on Cord Blood Banking and Adult Unrelated Donors in Hematopoietic Cell Transplantation: The Canadian Blood Services Experience.
    Biol Blood Marrow Transplant 2017 Dec 15. Epub 2017 Dec 15.
    Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Canadian Blood Services, OneMatch Stem Cell and Marrow Network, Ottawa, Ontario, Canada; Cord Blood Bank, Ottawa, Ontario, Canada; Medical Microbiology, Toronto Ontario, Canada; Centre for Transfusion Research, The Ottawa Hospital, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:
    Zika virus has emerged as a potential threat to the Canadian blood supply system. Stem cell donors within Canadian Blood Services' Cord Blood Bank (CBB) and OneMatch Stem Cell and Marrow Network (OM) now undergo screening measures designed to reduce the risk of Zika virus transmission. The impact these screening measures have on cord blood and unrelated adult stem cell donations is currently unknown. Read More

    Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.
    Biol Blood Marrow Transplant 2017 Dec 13. Epub 2017 Dec 13.
    Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR 7258, Marseille, France; Medical Faculty, Aix-Marseille University, UM 105, Marseille, France. Electronic address:
    We evaluated the impact of unidirectional donor versus recipient killer cell immunoglobulin-like receptor (KIR)-ligand mismatch (KIR-Lmm) on the outcomes of T cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) in a cohort of 144 patients treated for various hematologi diseases. We separately analyzed 81 patients in complete remission (CR group) and 63 with active disease (no CR group) at the time of Haplo-SCT. One-third of patients in each group had KIR-Lmm. Read More

    Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Group for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 13. Epub 2017 Dec 13.
    Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Sackler Medical School Tel-Aviv University, Tel Aviv, Israel; Acute Leukemia Working Party Office, Paris, France.
    Dose intensity of the conditioning regimen has significant impact on the outcomes after stem cell transplantation (SCT) for acute myeloid leukemia. Most studies have shown more relapse, less nonrelapse mortality (NRM), and similar overall survival after reduced-intensity and myeloablative conditioning. There are limited data on the dose equivalence and expected outcomes of treosulfan-based compared with busulfan-based conditioning. Read More

    Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Biol Blood Marrow Transplant 2017 Dec 13. Epub 2017 Dec 13.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing, China. Electronic address:
    Here we compare outcomes between the tyrosine kinase inhibitors (TKIs) plus chemotherapy regimen and allogeneic hematopoietic stem cell transplantation (transplantation cohort) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and explore factors associated with prognosis. Data from 145 Ph+ ALL patients were analyzed retrospectively. Patients were treated with imatinib plus chemotherapy and then transplantation or continuous TKIs with chemotherapy based on patient preference. Read More

    Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
    Biol Blood Marrow Transplant 2017 Dec 12. Epub 2017 Dec 12.
    Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
    Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smaller studies have reported late complications. In this large study we focus on the late (100 days post-transplant) GI complications in allogenic stem transplant recipients. Read More

    Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.
    Biol Blood Marrow Transplant 2017 Dec 12. Epub 2017 Dec 12.
    Center for Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland.
    Vinorelbine combined with filgrastim at a dose of 10 µg/kg of body weight (BW) per day is a reliable and well-tolerated regimen for mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma. This prospective, randomized, phase II study was initiated to assess the feasibility of a reduced filgrastim dosage. Vinorelbine was combined with either standard-dose filgrastim (10 µg/kg BW per day) or reduced-dose filgrastim (5 µg/kg BW per day). Read More

    BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
    Biol Blood Marrow Transplant 2017 Dec 11. Epub 2017 Dec 11.
    Department of Medicine, Blood & Marrow Transplant Center, Roswell Park Cancer Institute, Buffalo, New York.
    The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design. Read More

    Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
    Biol Blood Marrow Transplant 2017 Dec 11. Epub 2017 Dec 11.
    Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:
    Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. Read More

    Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.
    Biol Blood Marrow Transplant 2017 Dec 7. Epub 2017 Dec 7.
    Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.
    High-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) has been anecdotally prescribed in gray zone lymphoma (GZL), showing encouraging efficacy. We conducted a multicenter retrospective study aimed at assessing outcomes after auto-HCT in 32 patients with GZL treated at 9 transplantation centers in the United States. The median age of patients at transplantation was 38 years (range, 18 to 70 years), and the majority were male (n = 21; 66%). Read More

    Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 7. Epub 2017 Dec 7.
    Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
    Limited guidance exists for dosing melphalan for autologous stem cell transplantation (ASCT) in the obese patient population, because the current literature reports conflicting clinical outcomes between obese and nonobese patients. In 2014, the American Society for Blood and Marrow Transplantation published conditioning chemotherapy dosing guidelines for obese patients and recommended dosing of melphalan using actual body weight (ABW) in the body surface area calculation. The practice at Barnes-Jewish Hospital has consistently been to dose melphalan using adjusted body weight (AdBW), with a 20% correction when a patient weighs ≥120% of his or her ideal body weight (IBW). Read More

    Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis.
    Biol Blood Marrow Transplant 2017 Dec 6. Epub 2017 Dec 6.
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
    Patients with immunoglobulin light chain (AL) amyloidosis undergoing peripheral blood hematopoietic stem cell (PBSC) mobilization for autologous hematopoietic stem cell transplantation (auto-HCT) can experience significant morbidity and mortality. The purpose of this study was to characterize the adverse events and identify prognostic factors associated with the development of morbidity and mortality in patients with AL amyloidosis who had begun PBSC mobilization for auto-HCT. A retrospective study was performed in 101 consecutive patients with AL amyloidosis who underwent PBSC mobilization for auto-HCT between January 2006 and December 2013. Read More

    Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 6. Epub 2017 Dec 6.
    Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address:
    Idiopathic pneumonia syndrome (IPS) is a noninfectious pulmonary complication after hematopoietic cell transplantation (HCT) and is difficult to diagnose. In 41 patients with IPS, we evaluated 6 candidate proteins in plasma samples at day 7 post-HCT and at onset of IPS to identify potential diagnostic or prognostic biomarkers for IPS. Samples at similar times from 162 HCT recipients without documented infections and 37 HCT recipients with respiratory viral pneumonia served as controls. Read More

    Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
    Biol Blood Marrow Transplant 2017 Dec 5. Epub 2017 Dec 5.
    Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida; Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, Miami, Florida.
    The optimal viral load threshold at which to initiate preemptive cytomegalovirus (CMV) therapy in hematopoietic cell transplantation (HCT) recipients remains to be defined. In an effort to address this question, we conducted a retrospective study of 174 allogeneic HCT recipients who underwent transplantation at a single center between August 2012 and April 2016. During this period, preemptive therapy was initiated at the discretion of the treating clinician. Read More

    Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.
    Biol Blood Marrow Transplant 2017 Dec 2. Epub 2017 Dec 2.
    Division of Blood and Marrow Transplant, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
    Fanconi anemia (FA)-associated severe aplastic anemia (SAA) requires allogeneic hematopoietic cell transplantation (HCT) for cure. With the evolution of conditioning regimens over time, outcomes of alternative donor HCT (AD-HCT) have improved dramatically. We compared outcomes of HLA-matched sibling donor HCT (MSD-HCT; n = 17) and AD-HCT (n = 57) performed for FA-associated SAA at a single institution between 2001 and 2016. Read More

    T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
    Biol Blood Marrow Transplant 2017 Nov 29. Epub 2017 Nov 29.
    Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.
    Allogeneic hematopoietic stem cell transplantation (SCT) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) relapsing after autologous SCT (ASCT), but the incidence of disease relapse is still high. We performed a retrospective study on 64 patients with HL relapsing after ASCT to compare outcomes after HLA-identical SCT (HLAid-SCT; n = 34) and haploidentical SCT with post-transplantation cyclophosphamide (PT-Cy) (Haplo-SCT; n = 30). All patients engrafted, with a significantly shorter median time for neutrophil and platelet engraftment after HLAid compared with Haplo-SCT (14 days versus 19 days and 11 days versus 23 days, respectively; P < . Read More

    Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Dec 26. Epub 2017 Dec 26.
    Department of Laboratory Medicine-Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address:
    Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for patients with a hematologic malignancy due to alloreactive T cell responses recognizing minor histocompatibility antigens (MiHA). Yet tumor immune escape mechanisms can cause failure of T cell immunity, leading to relapse. Tumor cells display low expression of costimulatory molecules and can up-regulate coinhibitory molecules that inhibit T cell functionality on ligation with their counter-receptors on the tumor-reactive T cells. Read More

    1 OF 80